Efg Asset Management (North America) Corp. Bei Gene, Ltd. Transaction History
Efg Asset Management (North America) Corp.
- $580 Million
- Q1 2025
A detailed history of Efg Asset Management (North America) Corp. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 7,620 shares of BGNE stock, worth $1.73 Million. This represents 0.3% of its overall portfolio holdings.
Number of Shares
7,620
Previous 9,986
23.69%
Holding current value
$1.73 Million
Previous $1.84 Million
6.34%
% of portfolio
0.3%
Previous 0.26%
Shares
8 transactions
Others Institutions Holding BGNE
# of Institutions
295Shares Held
40.1MCall Options Held
111KPut Options Held
114K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion23.78% of portfolio
-
Capital International Investors Los Angeles, CA5.09MShares$1.15 Billion0.24% of portfolio
-
Primecap Management CO Pasadena, CA5.06MShares$1.15 Billion0.97% of portfolio
-
Baillie Gifford & CO3.63MShares$823 Million0.74% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.71MShares$615 Million0.09% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...